Brief Report
Volume 09:03, 2024

Journal of Molecular Histology and Medical Physiology

ISSN: 2684-494X

Open Access

Genetic Predispositions and their Role in Breast Cancer Development

Luis Elian*

Department of Medicine, University of South Carolina School of Medicine Greenville, Greenville, SC 29605, USA

Introduction

Breast cancer is a significant health concern worldwide, affecting millions of women each year. While environmental factors and lifestyle choices contribute to breast cancer risk, genetic predispositions play a crucial role in its development. Understanding the genetic factors involved in breast cancer can help in early detection, prevention, and personalized treatment strategies. This article delves into the genetic predispositions associated with breast cancer, highlighting key genes, their mechanisms, and the implications for patient care.

Genetic predispositions refer to the increased likelihood of developing a disease due to specific genetic variations inherited from one's parents. In breast cancer, several genes have been identified that significantly elevate the risk of developing the disease. These genes can be broadly categorized into high-penetrance genes, moderate-penetrance genes, and low-penetrance genes, depending on the degree of risk they confer [1].

The most well-known high-penetrance genes associated with breast cancer are BRCA1 and BRCA2. Mutations in these genes are responsible for a substantial proportion of hereditary breast cancer cases. Women with BRCA1 or BRCA2 mutations have a significantly higher risk of developing breast cancer compared to the general population.

BRCA1 and BRCA2 are tumor suppressor genes involved in DNA repair mechanisms. When these genes are mutated, the ability to repair DNA damage is compromised, leading to genomic instability and increased cancer risk. BRCA1 mutations are also associated with a higher likelihood of developing triple-negative breast cancer, a particularly aggressive form of the disease [2].

Another high-penetrance gene linked to breast cancer is TP53, which encodes the p53 protein. P53 is known as the "guardian of the genome" because of its role in maintaining genomic integrity. Mutations in TP53 are associated with Li-Fraumeni syndrome, a hereditary condition that significantly increases the risk of various cancers, including breast cancer. Women with TP53 mutations have a lifetime breast cancer risk of up to 85%.

PALB2 (Partner and Localizer of BRCA2) is another gene associated with an increased risk of breast cancer. It interacts with BRCA2 in DNA repair processes. Mutations in PALB2 can impair DNA repair, similar to BRCA1 and BRCA2 mutations. Women with PALB2 mutations have a breast cancer risk that is approximately three to four times higher than the general population [3].

CHEK2 is a gene that encodes a protein involved in DNA damage response and cell cycle control. Mutations in CHEK2 are associated with a moderate increase in breast cancer risk. The most common CHEK2 mutation, 1100delC, is particularly prevalent in certain populations, such as those of Northern and Eastern European descent. Women with this mutation have a twofold to threefold increased risk of breast cancer [4].

Low-penetrance genes individually contribute to a smaller increase in breast cancer risk but can collectively have a significant impact. These genes often involve single nucleotide polymorphisms (SNPs) that are common in the population. While each SNP may only slightly elevate the risk, the presence of multiple risk alleles can compound the overall risk.

The identification of genetic predispositions to breast cancer has significant implications for patient care. Genetic testing can identify individuals with mutations in high- and moderate-penetrance genes, enabling targeted surveillance, risk-reducing strategies, and personalized treatment plans.

For individuals with a family history of breast cancer or known genetic mutations, genetic counseling is crucial. Genetic counselors provide information about the implications of genetic test results, guide decision-making regarding preventive measures (such as prophylactic mastectomy or oophorectomy), and offer psychological support [5].

Description

Understanding genetic predispositions to breast cancer allows for the implementation of preventive strategies. For high-risk individuals, options include increased surveillance (such as regular mammograms and MRI screenings), chemoprevention (using medications like tamoxifen or raloxifene), and prophylactic surgeries.

Moreover, knowledge of genetic mutations can influence treatment decisions. For example, PARP inhibitors are a class of drugs that have shown efficacy in treating breast cancers associated with BRCA1 and BRCA2 mutations. These drugs exploit the defective DNA repair mechanisms in cancer cells, leading to cell death.

Conclusion

Genetic predispositions play a pivotal role in the development of breast cancer. High-penetrance genes such as BRCA1, BRCA2, and TP53 significantly increase the risk, while moderate- and low-penetrance genes contribute to varying extents. Advances in genetic testing and counseling have revolutionized the management of hereditary breast cancer, offering opportunities for early detection, personalized prevention, and targeted therapies. As research continues, a deeper understanding of genetic predispositions will further enhance our ability to combat breast cancer effectively.

Acknowledgement

None.

Conflict of Interest

None.

***Address for Correspondence:** Luis Elian, Department of Medicine, University of South Carolina School of Medicine Greenville, Greenville, SC 29605, USA; E-mail: elian@luis.sc.edu*

Received: 20 April, 2024, Manuscript No. jmhmp-24-140968; **Editor Assigned:** 22 April, 2024, PreQC No. P-140968; **Reviewed:** 06 May, 2024, QC No. Q-140968; **Revised:** 13 May, 2024, Manuscript No. R-140968; **Published:** 20 May, 2024, DOI: 10.37421/2684-494X.2024.9.226

References

1. Piragine, Eugenia, Davide Petri, Alma Martelli and Vincenzo Calderone, et al. "Adherence to oral antidiabetic drugs in patients with type 2 diabetes: systematic review and meta-analysis." *J Clin Med* 12 (2023): 1981.
2. Derosa, Giuseppe, Angela D'Angelo, Davide Romano and Pamela Maffioli, et al. "Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes." *Drug Des Devel Ther* 2017: 1481-1488.
3. Tan, Jixue, Yang Wang, Song Liu and Qingyang Shi, et al. "Long-acting metformin vs. metformin immediate release in patients with type 2 diabetes: A systematic review." *Front Pharmacol* 12: 669814.
4. Walker, Josephine, Betty B. Chaar, Numa Vera and Alvish S. Pillai, et al. "Medicine shortages in Fiji: A qualitative exploration of stakeholders' views." *PloS One* 12: e0178429.
5. Said, André, Ralf Goebel, Matthias Ganso and Petra Zagermann-Muncke, et al. "Drug shortages may compromise patient safety: Results of a survey of the reference pharmacies of the Drug Commission of German Pharmacists." *Health Policy* 122: 1302-1309.

How to cite this article: Elian, Luis. "Genetic Predispositions and their Role in Breast Cancer Development." *J Mol Hist Med Phys* 9 (2024): 226.